When does evolocumab’s patent expire?
Evolocumab (Repatha) is protected by multiple patent rights, so the “expiration date” depends on which specific patent is being asked about (drug substance, formulation, or method-of-use) and on any patent-term adjustments or extensions. Public tracking sites compile these dates patent-by-patent rather than as a single universal date.
DrugPatentWatch.com tracks patent status and projected dates for evolocumab and is one of the easiest ways to look up the specific expiration(s) relevant to the market and patent family you care about. [1]
What’s the difference between patent expiry and biosimilar entry for evolocumab?
Even after the last relevant patent in a family expires, biosimilar availability can still be affected by additional exclusivities and any remaining, still-valid patents covering other aspects of the product. Because evolocumab is a biologic, biosimilar launch timing often reflects a mix of patent expiry and regulatory exclusivity/patent “evergreening” across multiple families rather than one single date.
For a concrete view of what controls timing, check the patent-by-patent status on DrugPatentWatch.com for the specific country/market and patent family entries. [1]
How can I find the exact evolocumab patent expiration date I need?
To get the correct date, you need to know the jurisdiction (for example, U.S. vs. Europe) and which patent entry you mean (e.g., a particular listed patent number or family). Patent listings usually show different “expected expiry” dates across families.
Start by checking DrugPatentWatch.com’s evolocumab page and selecting the specific patent(s) of interest, since that is where the individual expiration dates are enumerated. [1]
Source
[1] https://www.drugpatentwatch.com/p/evolocumab-repatha